**Fintel Reports Coverage Initiation of Jazz Pharmaceuticals**
On May 22, 2026, Bernstein initiated coverage of Jazz Pharmaceuticals (NasdaqGS:JAZZ) with a “Market Perform” recommendation. The average one-year price target for the company stands at $247.51 per share, reflecting a potential upside of 3.39% from its latest closing price of $239.40 per share.
Projected annual revenue for Jazz Pharmaceuticals is estimated at $4,097 million, a decrease of 7.70%. Current fund sentiment shows a significant drop, with 591 funds reporting positions, down 332 (35.97%) from the previous quarter. Institutional ownership declined by 4.20% to 70.83 million shares, while the put/call ratio stands at 0.79, indicating a bullish outlook.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
